Skip to content

The effect of nebulized esketamine inhalation on postoperative sore throat following double-lumen endotracheal intubation

The effect of nebulized esketamine inhalation on postoperative sore throat following double-lumen endotracheal intubation

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500107277
Enrollment
Unknown
Registered
2025-08-07
Start date
2025-08-07
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative sore throat

Interventions

C group with nebulized normal saline:Twenty minutes before anesthesia induction, pour 5 mL of normal saline into the nebulizer and instruct the patient to inhale the nebulized solution, with an estima
C group with nebulized esketamine group:Twenty minutes prior to anesthesia induction, mix 25 mg of esketamine (50 mg/mL, Hengrui Pharmaceuticals, Jiangsu, China) with 4 mL of normal saline to a total
K2 group intravenous administration of esketamine group :Prior to endotracheal intubation, the patient received 25 mg of esketamine via intravenous injection.

Sponsors

The Second Hospital of Dalian Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.>=18 years old; 2.American Society of Anesthesiologists (ASA) physical status I-III; 3.Scheduled for elective surgery under general anesthesia with double-lumen endobronchial intubation; 4.Patients who provided written informed consent.

Exclusion criteria

Exclusion criteria: 1.Known allergy to esketamine; 2.Known or anticipated difficult airway, defined as Mallampati class IV or Cormack-Lehane grade III-IV on laryngoscopy; 3.Pre-existing sore throat, hoarseness, or recent/recurrent respiratory tract infection; 4.Anticipated risk of aspiration; 5.Requirement of oropharyngeal or nasopharyngeal airway during mask ventilation; 6.Poorly controlled or untreated hypertension. 7. Conditions associated with elevated intracranial pressure (ICP), increased intraocular pressure (IOP), or ischemic heart disease; 8. Patients assessed to be at high risk of delirium or otherwise contraindicated for esketamine administration based on comprehensive evaluation.

Design outcomes

Primary

MeasureTime frame
Incidence and severity (Grade 0-3) of postoperative sore throat and hoarseness ;

Secondary

MeasureTime frame
Incidence and severity of dry mouth and cough;Mean arterial pressure and heart rate;Resting and cough-induced wound pain Numeric Rating Scale (NRS) scores ;Postoperative adverse reactions including hallucinations, nausea/vomiting, and agitation;

Countries

China

Contacts

Public ContactHaitao Yang

The Second Hospital of Dalian Medical University

litingting0608@163.com+86 134 7874 6652

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026